Savoy Equities looking toward PNG as malaria trials continue

Savoy Equities, the oils and resins extraction business working towards manufacturing an anti-malarial product, is looking to tap the market in Papua New Guinea amid “very encouraging” trials of the company’s Artemisia herbal capsules.  

The company’s managing director Garrick Wells has been in discussions with health department and government officials amid trials in rural PNG that have shown better outcomes than the medication patients were previously on. More than 200 patients in the trial exhibited “highly promising results” according to the company’s annual report.  

The Artemisia capsules are herbal-based, and won’t require a medical prescription, broadening the availability of the treatment if and when it becomes distributed, Wells said in a statement.  

Savoy reported a $172,000 loss in the six months ended June 30 and the shares, which trade infrequently, have climbed 25% to 1.5 cents in the past year.  

Wells said the company’s capsules use a much smaller amount of pure artemisinin with and would offer a “highly cost effective means of alleviating symptoms” of malaria.  

Businesswire.co.nz

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.